Cytek Biosciences, Inc.
CTKB
$4.31
-$0.06-1.26%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -704.60% | 1.88% | 51.03% | -218.24% | 925.85% |
| Total Depreciation and Amortization | -0.56% | 2.41% | 3.61% | 5.22% | -2.42% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,999.71% | -40.28% | -34.97% | 209.76% | -178.66% |
| Change in Net Operating Assets | 2.47% | -353.89% | -125.92% | 155.07% | -268.76% |
| Cash from Operations | 80.22% | -3,709.26% | 186.40% | -106.26% | -84.90% |
| Capital Expenditure | -52.36% | 58.34% | -85.75% | 5.03% | 11.57% |
| Sale of Property, Plant, and Equipment | 19,400.00% | -95.65% | -30.30% | -82.72% | 809.52% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -105.29% | 231.75% | -244.71% | 116.49% | -320.13% |
| Cash from Investing | -109.74% | 215.27% | -273.65% | 114.90% | -301.25% |
| Total Debt Issued | -32.28% | 50.97% | 100.72% | -75.22% | 55,600.00% |
| Total Debt Repaid | -1,927.59% | -2.11% | 90.65% | -992.09% | 0.71% |
| Issuance of Common Stock | 287.59% | -82.14% | 1,866.67% | -95.33% | 468.03% |
| Repurchase of Common Stock | -64.79% | 96.92% | 57.12% | -51.05% | 41.13% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -163.16% | 174.60% | 77.46% | -217.17% | 69.88% |
| Foreign Exchange rate Adjustments | 66.90% | 191.86% | 25.00% | -180.90% | 260.98% |
| Miscellaneous Cash Flow Adjustments | -- | 200.00% | -- | -- | -- |
| Net Change in Cash | -113.63% | 189.82% | -475.42% | 94.58% | -307.03% |